Evidence map›Paper›PMID 32446821›Full record

ArticleJournal of the American Academy of Dermatology2020

Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: The "Gabrin sign".

Carlos Gustavo Wambier, Sergio Vaño-Galván, John McCoy, Alba Gomez-Zubiaur, Sabina Herrera, Ángela Hermosa-Gelbard, Oscar M Moreno-Arrones, Natalia Jiménez-Gómez, Alvaro González-Cantero, Pablo Fonda-Pascual and 4 more

3 registry-linked trialsAbstract readLetterMulticenter Study
In one paragraph

Article in Journal of the American Academy of Dermatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 91 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
91citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04446429 nacompletednot on this map

Anti-Androgen Treatment for COVID-19

TypeinterventionalSponsorApplied Biology, Inc.Ran2020 to 2021Enrolled268ConditionsCOVID-19, SARS-CoV2, Androgenetic Alopecia, Prostate CancerArmsProxalutamide, Standard of Care
NCT04728802 phase3completednot on this mapstarted 2021, after this paper: background citation

Proxalutamide Treatment for Hospitalized COVID-19 Patients

TypeinterventionalSponsorApplied Biology, Inc.Ran2021 to 2021Enrolled645ConditionsCovid19, SARS (Severe Acute Respiratory Syndrome)ArmsProxalutamide, Placebo
NCT04898166 completednot on this map

Association of Androgenetic Alopecia and Severity of Coronavirus Disease 2019 (COVID-19)

Typeobservational_patient_registrySponsorSyeda Mahanum AliRan2020 to 2021Enrolled300ConditionsAndrogenetic Alopecia, Coronavirus Disease 2019, Covid19, Male Pattern Baldness
3 · Its place in the literature

Who cites it

91 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Observational
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Observational
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review

31 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Carlos Gustavo WambierDepartment of Dermatology, Alpert Medical School of Brown University, Providence, Rhode Island. Electronic address: carlos_wambier@brown.edu.
Sergio Vaño-GalvánDermatology Department, Ramón y Cajal Hospital, Madrid, Spain.
John McCoyApplied Biology, Inc, Irvine, California.
Alba Gomez-ZubiaurDermatology Department, Hospital Principe de Asturias, Alcalá de Henares, Madrid, Spain.
Sabina HerreraInfectious Diseases Unit, Ramón y Cajal Hospital, Madrid, Spain.
Ángela Hermosa-GelbardDermatology Department, Ramón y Cajal Hospital, Madrid, Spain.
Oscar M Moreno-ArronesDermatology Department, Ramón y Cajal Hospital, Madrid, Spain.
Natalia Jiménez-GómezDermatology Department, Ramón y Cajal Hospital, Madrid, Spain.
Alvaro González-CanteroDermatology Department, Ramón y Cajal Hospital, Madrid, Spain.
Pablo Fonda-PascualDermatology Department, Hospital Central de la Defensa, Madrid, Spain.
Gonzalo Segurado-MiravallesDermatology Department, Ramón y Cajal Hospital, Madrid, Spain.
Jerry ShapiroRonald O. Perelman Department of Dermatology at the New York University School of Medicine, New York, New York.
Bibiana Pérez-GarcíaDermatology Department, Ramón y Cajal Hospital, Madrid, Spain.
Andy GorenApplied Biology, Inc, Irvine, California.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Severity of Illness IndexAdultAgedAged, 80 and overAlopeciaAndrogen AntagonistsAndrogensBetacoronavirusCoronavirus InfectionsCOVID-19COVID-19 Drug TreatmentFemaleHumansMaleMiddle AgedPandemicsAndrogen AntagonistsAndrogensAR protein, humanReceptors, Androgen

Identifiers

PMID32446821
PMCPMC7242206

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.